[CLSTR]
< Back to situation

[REVISION HISTORY]

Celltrion biosimilar market expansion

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-03 05:13 UTC → 2026-09-17 01:23 UTC · added removed

Celltrion has demonstrated significant financial and market growth driven by continues to expand its global biosimilar portfolio. In its second-quarter 2025 results, the company reported sales of 1.3937 trillion won and an operating profit of 451.8 billion won, representing year-on-year increases of 45% and 86.3% respectively. This performance was largely supported by newer biosimilars, which accounted for 65% of total sales. Market data from IQVIA for the first quarter of 2024 highlights Celltrion’s dominance in Asian markets. The autoimmune treatment Remsima (infliximab) secured top market positions share, particularly in Singapore (93%), Hong Kong (84%), Thailand (78%), autoimmune and Malaysia (72%). In the oncology sector, Truxima (rituximab) ranked first in Singapore and Thailand, while Herzuma (trastuzumab) led in Malaysia and Thailand. Additionally, the colorectal and breast cancer treatment Vegelma (bevacizumab) rose to a 30% market share in Malaysia by the first quarter of 2024. Expanding its global footprint, Celltrion has reported significant growth in treatments. In the United States and Europe. In States, the U.S. ustekinumab market, the biosimilar Stekyma reached a 16.2% market share in July. July, marking a 6 percentage point increase over five months. The company’s oncology portfolio also shows strength remains strong in the U.S., with Truxima holding 38.6% and Inflectra at 30.7%. In Europe, the subcutaneous formulation Remsima SC has achieved record shares in the EU5, including 49% in Germany, 35% in France, and 31% in Italy. Asian markets remain a stronghold; Remsima maintains dominant positions in Singapore (93%), Hong Kong (84%), Thailand (78%), and Malaysia (72%). A significant milestone was reached in Japan, where Remsima (infliximab) secured a 48% market share in July, surpassing original brand-name drugs for the first time since its launch 11 years ago. Celltrion attributes these successes attributed this in Japan to a dual-track distribution strategy involving its local partner, Nippon Kayaku, and its own Japanese subsidiary. Other products in Japan include Yuflyma (adalimumab) at 21% market share, Herzuma (trastuzumab) at 78%, and Vegzelma (bevacizumab) at 64%. Celltrion plans to leverage its direct sales networks, localized strategies, networks to launch high-margin products like Omlyclo and inclusion intends to launch Remsima SC in major Pharmacy Benefit Manager (PBM) formularies. Japan in 2027.

Versions

  1. 2026-09-17 01:23 UTC Celltrion biosimilar market expansion
  2. 2026-09-03 05:13 UTC Celltrion biosimilar market expansion
  3. 2026-08-19 02:47 UTC Celltrion biosimilar market expansion

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.